Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA's NDA And BLA Approvals: Lonhala Magnair, Ozempic

Executive Summary

Original new drugs and biologics recently approved by US FDA.

You may also be interested in...



Glenmark’s Lonhala Version Hits ‘Intriguing’ Indian Nebulizer Market

Glenmark’s nebulized, long-acting muscarinic antagonist for COPD has hit the Indian market. Delivered via a novel mesh nebulizer, it is seen as likely catering to a relatively small patient group.

Lilly, Novartis, Jazz and Ionis Take New Products To EMA

Lilly’s migraine prevention therapy, galcanezumab, is among the nine new products that companies have submitted to the European Medicines Agency for evaluation in recent weeks.

Orphans Dominate Products Seeking End-Of-Year Joy From CHMP

Five of the nine products that could this week be recommended for EU approval have orphan designation. The final meeting this year of the European Medicines Agency’s key scientific committee, the CHMP, is under way in London.

Related Content

Topics

UsernamePublicRestriction

Register

PS122102

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel